Menopausal hormone therapy: a better and safer future

References

• Caruso S, Cianci S, Vitale SG, Matarazzo MG, Amore FF, Cianci A. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause 2017;24:900–7
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139–47
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greybar E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;(3):CD002229
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. and the IMS writing group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–15
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24:1–26
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health 2006;15:35–44
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, ELITE Research Group, et al. Effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas H. Molecular and cellular basis of cardiovascular gender differences. Science 2005;38:1583–7
   Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80
   PubMed Web of Science ®Google Scholar
• Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031–41
   PubMed Web of Science ®Google Scholar
• Scarabin P-V, Oger E, Plu-Bureau G. on behalf of the EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy venous thromboembolism among postmenopausal women: impact of the route of administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N cohort study. Arterioscl Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10:2277–86
   PubMed Web of Science ®Google Scholar
• Roach RE, Lijfering WM, Helmerhorst FM, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013;11:124–31
   PubMed Web of Science ®Google Scholar
• Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Marars L. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 2016;23:593–9
   PubMed Web of Science ®Google Scholar
• Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 2016;23:600–10
   PubMed Web of Science ®Google Scholar
• Lowe GD, Upton MN, Rumley A, McConnachie A, O’reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein – a cross-sectional population survey. Thromb Haemost 2001;86:550–6
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progestins regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671–6
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071–8
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveria A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation and fibrinolysis in postmenopausal women. Thromb Haemost 2001;85:619–25
   PubMed Web of Science ®Google Scholar
• Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus prometrium administered orally in postmenopausal women(3). Fertil Steril 2007;73:516–21
   Google Scholar
• Kuhl H, Schneider HPG. Progesterone – promoter or inhibitor of breast cancer. Climacteric 2013;16(Suppl 1:):54–68
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008. Am J Epidemiol 2014;180:508–17
   PubMed Web of Science ®Google Scholar
• Sjogren LL, Morch LS, Lokkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016;91:25–35
   PubMed Web of Science ®Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer; what is the true size of the increased risk?. Br J Cancer 2016;115:607–15
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• Stute P. Is breast cancer risk the same for all progestogens?. Arch Gynecol Obstet 2014;290:207–9
   PubMed Web of Science ®Google Scholar
• Cincinelli E, de Ziegler D, Bulleti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2009;95:403–6
   Google Scholar
• Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485–90
   PubMed Web of Science ®Google Scholar
• Bulleti C, de Ziegler D, Flaigni C, et al. Targeted drug delivery in gynaecology; the first uterine pass effect. Hum Reprod 1997;12:1073–9
   PubMed Web of Science ®Google Scholar
• De Ziegler D, Bulleti C, De Monstier B, Jääskeläinen AS. The first uterine pass effect. Ann N Y Acad Sci 1997;828:291–9
   PubMed Web of Science ®Google Scholar
• Seeber B, Ziehr SC, Gschlieβer A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 2012;86:345–9
   PubMed Web of Science ®Google Scholar
• Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral estrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002;109:136–44
   Google Scholar
• Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813–17
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonogestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211–17
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EIA. case-control study on hormone therapy as risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grenman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292–9
   PubMed Web of Science ®Google Scholar
• Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 2009;80:84–9
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529–36
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F. Use of the levonorgestrel intrauterine system in postmenopause. Climacteric 2015;18:431–2
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F. Levonorgestrel and breast cancer risk - clarified. Climacteric 2015;18:434
   PubMed Web of Science ®Google Scholar
• Wildemeersch D. Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution – a review. Gynecol Endocrinol 2016;32:598–601
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–9
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flushes after natural menopause: evidence from the penn ovarian aging study cohort. Menopause 2014;21:924–32
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sutton-Tyrell K, Everson-Rose SA, Hess R, Powell LH, Mathews KA. Hot flashes and carotid intima media thickness among mid-life women. Menopause 2011;18:352–8
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015;100:523–34
   Web of Science ®Google Scholar